Background: Accurate delineation of tumors and organs at risk (OARs) is crucial for intensity-modulated radiation therapy. This study aimed to evaluate the performance of OncoStudio, an AI-based auto-segmentation tool developed for Korean patients, compared with Protégé AI, a globally developed tool that uses data from Korean cancer patients. Methods: A retrospective analysis of 1200 Korean cancer patients treated with radiotherapy was conducted. Auto-contours generated via OncoStudio and Protégé AI were compared with manual contours across the head and neck and thoracic, abdominal, and pelvic organs. Accuracy was assessed using the Dice similarity coefficient (DSC), mean surface distance (MSD), and 95% Hausdorff distance (HD). Feedback was obtained from 10 participants, including radiation oncologists, residents, and radiation therapists, via an online survey with a Turing test component. Results: OncoStudio outperformed Protégé AI in 85% of the evaluated OARs (p< 0.001). For head and neck organs, OncoStudio achieved a similar DSC (0.70 vs. 0.70,p= 0.637) but significantly lower MSD and 95% HD values (p< 0.001). In thoracic organs, OncoStudio performed excellently in 90% of cases, with a significantly greater DSC (male: 0.87 vs. 0.82,p< 0.001; female: 0.95 vs. 0.87,p< 0.001). OncoStudio also demonstrated superior accuracy in abdominal (DSC 0.88 vs. 0.81,p< 0.001) and pelvic organs (male: DSC 0.95 vs. 0.85,p< 0.001; female: DSC 0.82 vs. 0.73,p< 0.001). Clinicians favored OncoStudio in 70% of cases, with 90% endorsing its clinical suitability for Korean patients. Conclusions: OncoStudio, which is tailored for Korean patients, demonstrated superior segmentation accuracy across multiple anatomical regions, suggesting its suitability for radiotherapy planning in this population.
背景：精确勾画肿瘤及危及器官（OARs）对调强放射治疗至关重要。本研究旨在评估基于韩国患者数据开发的AI自动勾画工具OncoStudio与采用韩国癌症患者数据的全球开发工具Protégé AI的性能差异。 方法：对1200例接受放射治疗的韩国癌症患者进行回顾性分析。通过OncoStudio和Protégé AI生成的自动勾画结果与头颈部、胸部、腹部及盆腔器官的手动勾画结果进行对比。采用戴斯相似系数（DSC）、平均表面距离（MSD）及95%豪斯多夫距离（HD）评估准确性。通过包含图灵测试的在线调查，收集了10名参与者（包括放射肿瘤科医师、住院医师和放射治疗师）的反馈。 结果：OncoStudio在85%的危及器官评估中表现优于Protégé AI（p<0.001）。对于头颈部器官，OncoStudio的DSC值相近（0.70 vs. 0.70，p=0.637），但MSD和95% HD值显著更低（p<0.001）。在胸部器官中，OncoStudio在90%的病例中表现优异，DSC值显著更高（男性：0.87 vs. 0.82，p<0.001；女性：0.95 vs. 0.87，p<0.001）。OncoStudio在腹部（DSC 0.88 vs. 0.81，p<0.001）和盆腔器官（男性：DSC 0.95 vs. 0.85，p<0.001；女性：DSC 0.82 vs. 0.73，p<0.001）中也显示出更高的准确性。临床医师在70%的病例中更倾向于使用OncoStudio，其中90%认为其适用于韩国患者的临床需求。 结论：针对韩国患者优化的OncoStudio在多个解剖区域展现出更优的勾画准确性，表明其适用于该人群的放射治疗计划设计。
肿瘤(癌症)患者之家